晚期癌症患者对免疫治疗的风险、获益和治疗潜力的认知。
Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
机构信息
Division of Palliative Care and Geriatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
Oncologist. 2021 Nov;26(11):e2090-e2093. doi: 10.1002/onco.13945. Epub 2021 Aug 28.
Abstract
BACKGROUND
Immunotherapy is the first-line treatment for melanoma and lung cancer and brings new risks of immune-related adverse events. We aimed to describe patients' knowledge about risks, benefits, and goals of immunotherapy.
MATERIALS AND METHODS
We conducted a cross-sectional study of patients with advanced melanoma or non-small cell lung cancer that used a 9-item knowledge survey and questions from the Prognosis and Treatment Perceptions Questionnaire.
RESULTS
We surveyed 105 participants (57 with melanoma, 48 with lung cancer) with median age 69 years (range 36-89). Participants' responses revealed knowledge deficits about immunotherapy mechanism of action and lack of awareness about the timing and severity of side effects. One third (34%; 36/105) of participants reported that the primary goal of their treatment is to cure their cancer.
CONCLUSION
Given the widespread use of immunotherapy, patients would benefit from educational tools so that they know what to expect regarding side effects and prognosis.
摘要
背景
免疫疗法是治疗黑色素瘤和肺癌的一线疗法，会带来新的免疫相关不良反应风险。我们旨在描述患者对免疫疗法的风险、获益和目标的认知。
材料和方法
我们开展了一项横断面研究，纳入了晚期黑色素瘤或非小细胞肺癌患者，使用了 9 项知识调查问卷和预后和治疗认知问卷中的问题。
结果
我们调查了 105 名参与者（57 名黑色素瘤患者，48 名肺癌患者），中位年龄为 69 岁（范围 36-89 岁）。参与者的回答显示，他们对免疫疗法作用机制的知识存在不足，并且对副作用的发生时间和严重程度缺乏认识。三分之一（34%；36/105）的参与者表示，他们治疗的主要目标是治愈癌症。
结论
鉴于免疫疗法的广泛应用，患者需要教育工具，以便了解副作用和预后方面的预期。
相似文献
1
Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.晚期癌症患者对免疫治疗的风险、获益和治疗潜力的认知。
Oncologist. 2021 Nov;26(11):e2090-e2093. doi: 10.1002/onco.13945. Epub 2021 Aug 28.
2
3
[A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].[真实世界中接受免疫治疗的晚期非小细胞肺癌患者的单中心分析]
Zhongguo Fei Ai Za Zhi. 2019 Nov 20;22(11):687-695. doi: 10.3779/j.issn.1009-3419.2019.11.02.
4
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?抗程序性细胞死亡蛋白 1 治疗在转移性黑色素瘤和非小细胞肺癌患者中的耐受性的性别差异：我们都平等吗？
Oncologist. 2019 Nov;24(11):e1148-e1155. doi: 10.1634/theoncologist.2019-0094. Epub 2019 Apr 29.
5
Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients.采用癌症免疫疗法治疗的晚期或转移性非小细胞肺癌患者的数字监测和管理及其对临床护理质量的影响：医疗保健专业人员和患者的访谈和调查研究。
J Med Internet Res. 2020 Dec 21;22(12):e18655. doi: 10.2196/18655.
6
Immune Checkpoint Inhibitors in Lung Cancer and Melanoma.免疫检查点抑制剂在肺癌和黑色素瘤中的应用。
Semin Oncol Nurs. 2019 Oct;35(5):150932. doi: 10.1016/j.soncn.2019.08.011. Epub 2019 Sep 25.
7
Predictors of immunotherapy-induced immune-related adverse events.免疫治疗诱导的免疫相关不良事件的预测因素。
Curr Oncol. 2018 Oct;25(5):e403-e410. doi: 10.3747/co.25.4047. Epub 2018 Oct 31.
8
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.PD-1与CTLA-4免疫检查点抑制剂联合治疗及姑息性放射治疗耐受性的多中心评估
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):344-351. doi: 10.1016/j.ijrobp.2017.02.003. Epub 2017 Feb 11.
9
Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.真实世界证据和 PD-1/PD-L1 抑制剂治疗晚期非小细胞肺癌的临床观察。
Sci Rep. 2019 Mar 12;9(1):4278. doi: 10.1038/s41598-019-40748-7.
10
Duration of immunotherapy - should we continue ad infinitum?免疫治疗的持续时间——我们应该无限期地持续下去吗？
Intern Med J. 2020 Jul;50(7):865-868. doi: 10.1111/imj.14919.
引用本文的文献
1
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH).关于免疫检查点抑制剂的肿瘤学家与患者沟通的混合方法分析（COACH）。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf064.
2
Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial.使用对话工具（iDECIDE）改善肺癌决策：一项阶梯楔形实用临床试验。
Future Oncol. 2025 Apr;21(9):1045-1056. doi: 10.1080/14796694.2025.2475733. Epub 2025 Mar 18.
3
Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers.了解和应对毒性：接受免疫检查点抑制剂治疗黑色素瘤或肺癌的患者及其护理者的定性研究。
Support Care Cancer. 2024 Sep 24;32(10):684. doi: 10.1007/s00520-024-08868-7.
4
Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative Study.患者及护理人员对免疫疗法的希望与预后不确定性的体验：一项定性研究。
JCO Oncol Pract. 2025 Feb;21(2):178-187. doi: 10.1200/OP.24.00299. Epub 2024 Jul 22.
5
Learning About and Living With Toxicity: A Qualitative Study of Patients Receiving Immune Checkpoint Inhibitors For Melanoma or Lung Cancer and Their Caregivers.了解毒性并与之共存：一项关于接受免疫检查点抑制剂治疗黑色素瘤或肺癌的患者及其护理人员的定性研究。
Res Sq. 2024 Jul 4:rs.3.rs-4576328. doi: 10.21203/rs.3.rs-4576328/v1.
6
A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer.一项探索接受免疫检查点抑制剂治疗晚期肺癌患者体验的定性研究。
Support Care Cancer. 2023 Jul 29;31(8):498. doi: 10.1007/s00520-023-07965-3.
7
Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study.免疫检查点抑制剂治疗泌尿生殖系统癌症患者的疗效感知变化：一项纵向研究。
Clin Genitourin Cancer. 2023 Dec;21(6):626-630.e3. doi: 10.1016/j.clgc.2023.05.018. Epub 2023 Jun 2.
8
Feasibility and preliminary effectiveness of virtual reality as a patient education tool for people with cancer undergoing immunotherapy: a protocol for a randomised controlled pilot study in a regional setting.虚拟现实作为癌症免疫治疗患者教育工具的可行性和初步效果：一项在区域环境中进行的随机对照初步研究方案。
BMJ Open. 2023 Jun 13;13(6):e071080. doi: 10.1136/bmjopen-2022-071080.
9
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.癌症免疫治疗学会（SITC）临床实践指南：免疫治疗治疗胃肠道癌。
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-006658.
10
Accuracy of curability expectations in patients with gastrointestinal cancers.胃肠道癌症患者对可治愈性的期望的准确性。
Cancer Med. 2023 Jan;12(1):20-29. doi: 10.1002/cam4.4947. Epub 2022 Jun 15.
本文引用的文献
1
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.接受 PD-1 阻断治疗的黑色素瘤患者的长期结果和再治疗应答。
J Clin Oncol. 2020 May 20;38(15):1655-1663. doi: 10.1200/JCO.19.01464. Epub 2020 Feb 13.
2
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
3
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
4
A cross-sectional study of patient and provider perception of "cure" as a goal of cancer surgery.一项关于患者和医疗服务提供者对“治愈”作为癌症手术目标的认知的横断面研究。
J Surg Oncol. 2016 Nov;114(6):677-683. doi: 10.1002/jso.24401. Epub 2016 Oct 3.
5
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
6
Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer.转移性肺癌和结直肠癌患者认为化疗可能治愈的信念以及临终时接受的护理。
Cancer. 2015 Jun 1;121(11):1891-7. doi: 10.1002/cncr.29250. Epub 2015 Feb 11.
7
Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.晚期癌症患者预后理解、生活质量和情绪之间的关系。
Cancer. 2014 Jan 15;120(2):278-85. doi: 10.1002/cncr.28369. Epub 2013 Oct 10.
8
Patients' expectations about effects of chemotherapy for advanced cancer.晚期癌症化疗效果的患者期望。
N Engl J Med. 2012 Oct 25;367(17):1616-25. doi: 10.1056/NEJMoa1204410.
9
Does age really matter? Recall of information presented to newly referred patients with cancer.年龄真的重要吗？对新转诊癌症患者所提供信息的回忆。
J Clin Oncol. 2008 Nov 20;26(33):5450-7. doi: 10.1200/JCO.2007.15.2322. Epub 2008 Oct 20.
10
Information needs and sources of information among cancer patients: a systematic review of research (1980-2003).癌症患者的信息需求与信息来源：一项研究的系统综述（1980 - 2003年）
Patient Educ Couns. 2005 Jun;57(3):250-61. doi: 10.1016/j.pec.2004.06.006.
Zotero 插件